Related Experiment Video
Updated: Mar 13, 2026
08:18
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
Published on: December 26, 2015
18.2K
Current Treatment of Multiple System Atrophy.
Sylvia Maaß1, Johannes Levin1,2, Günter Höglinger3
1Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) and Klinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, Feodor-Lynen Str. 17, 81377, Munich, Germany.
Current Treatment Options in Neurology
|October 28, 2016
Summary
Multiple system atrophy (MSA) treatment is currently symptomatic, with no disease-modifying options available. This review covers the current state of managing MSA symptoms, focusing on movement and autonomic disorders.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with no available disease-modifying treatments.
- Current therapeutic strategies for MSA are purely symptomatic.
Approach:
- This review discusses the current state of the art in managing multiple system atrophy.
- Focus is placed on symptomatic treatments for both motor and autonomic dysfunction.
Key Points:
- MSA presents with either parkinsonian (hypokinetic rigid) or cerebellar (ataxia) movement disorders.
- Autonomic symptoms are a mandatory diagnostic criterion and significantly impact quality of life.
- Dopaminergic therapy may offer partial relief for parkinsonian symptoms, but cerebellar symptoms lack effective treatment.
Conclusions:
- Effective symptomatic treatments for cerebellar ataxia in MSA are lacking.
- Management of autonomic symptoms is crucial for improving patient quality of life in MSA.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:28Drug Therapy
364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
364